2023-509961-19-00
Completed
Phase 1
Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 42
- Locations
- 1
- Status
- Completed
- Last Updated
- 10 months ago
Overview
Brief Summary
No summary available.
Investigators
EU Submission Hub
Scientific
Novo Nordisk A/S
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 1
A research study of a new medicine NNC0519-0130 in Japanese and non-Japanese metype 2 diabetesJPRN-jRCT2071230015Tsukasaki Nobuaki70
Completed
Not Applicable
Study of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple oral dosing in healthy subjects including brain Serotonin Transporter (SERT) occupancy by Positron Emission Tomography (PET).chronische pijn aan beschadigde organen.visceral painNL-OMON34068Eli Lilly51
Recruiting
Phase 1
Phase 1 study of 211At-MABG in patients with pheochromocytoma/pargangliomaPheochromocytoma, paragangliomaD010673, D010235JPRN-jRCT2021220012Shiga Tohru18
Not yet recruiting
Phase 1
Safety and pharmacokinetics of CIGB-552Solid tumorsRPCEC00000196Center for Genetic Engineering and Biotechnology (CIGB)
Completed
Not Applicable
A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orallyNL-OMON48072OP2 Drugs12